Deep remission is regarded as an important treatment goal for patients with Inflammatory bowel disease (IBD) towards modifying the disease course. It indicates complete disease quiescence with endoscopic score, rectal bleeding score, and stool frequency score of 0 and should be the culminating aim of the treatment. Higher rates of endoscopic healing are achieved with Vedolizumab, a gut-selective humanized monoclonal antibody. To elaborate more on this topic, Takeda and Docplexus have organized a webinar on 15th May 2020, Friday, 12:00 pm.
Join the international expert, Professor Rupert Leong who will be discussing his insights on Targeting deep remission in IBD with Vedolizumab. Disclaimer This information is solely intended for the use of Registered Medical Practitioner and Hospital only. This information should not be used or shared or distributed to any other person / party and…
